Decheng Capital

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Josh Ofman(Executive Officer)Robert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)

Board seatMin Cui· per SEC Form D

Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDentsu VenturesFelicis Ventures+8 more

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Co-investors3B Future Health FundAlly Bridge GroupVivo CapitalAvoro VenturesOrbiMed

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Executive Officer, Director)inHarlan Robins(Executive Officer)inKathleen Determann(Executive Officer)Dean Schorno(Executive Officer)Chris Carlson(Executive Officer)

BoardArnold Levine(Director)

Co-investorsFMG CapitalForesite CapitalKhosla VenturesOrbiMed

CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.

BiotechHealthtech

Co-investorsForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+2 more

Health Catalyst provides a data platform, analytics applications, and AI-powered insights that help healthcare organizations improve clinical, financial, and operational performance.

AI & Machine LearningData & InfrastructureDigital Health

Co-investorsEPIC VENTURESFifty YearsKaiser Permanente VenturesNorwest Venture PartnersOSF VenturesTenaya Capital+1 more

Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed.

BiotechHealthtechNew York, US

David Hung(Founder, President & Chief Executive Officer)

Co-investorsAisling CapitalEcoR1 CapitalVertex Ventures ChinaOmega Funds

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)Charles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)Jean-Yves Nothias(Director)

Co-investorsForesite Capital

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.

BiotechHealthtech

Rand Sutherlandin

Co-investorsAccess BiotechnologyBain Capital Life SciencesOrbiMedSamsara BioCapitalTCG CrossoverVenrock Healthcare Capital Partners

Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.

Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US

Fabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOmar Kurdi(Co-Founder and President)in

BoardJustin Butler(Director)inVictor Tong(Director)in

Co-investors8VCEcoR1 CapitalIntuitive VenturesKoch Disruptive TechnologiesBaillie GiffordBlackRock+4 more

Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection.

BiotechDeep TechHealthtech

David Johnson(Chief Executive Officer)Clayton Knox(President)Katti Jessen(SVP, Translational Sciences)Yakov Kogan(Head of Operations)Brian Lannutti(Research & Development Leadership)Langdon Miller(Clinical Development Leadership)

Co-investorsMatrix Capital ManagementYosemiteB Capital GroupB4 Capital

HealthtechHouston, US

Kengo Takishima(Executive Officer, Director)Joel Kaufman(Executive Officer)David Berger(Executive Officer)

BoardVictor Tong(Director)Goki Ishikawa(Director)

Board seatXiangmin Cui· per SEC Form D

BiotechMelrose, US

Richard Terry(Executive Officer, Director)Evan Daugharthy(Director)

BoardVictor Tong(Director)

Board seatMin CuiVictor Tong, Jr.· per SEC Form D · $18.1M raise · filed Aug 2026

West Hills, US

Board seatXiangmin Cui· per SEC Form D · $141.8M raise · filed Apr 2024

Co-investorsNovartis Venture FundRMGP Biopharma Investment FundvenBio Global Strategic

San Francisco, US

Utkan Demirci(Director)Lars Steinmetz(Director)Martin Pieprzyk(Executive Officer)

BoardXiangmin Cui(Director)Victor Tong(Director)

Board seatVictor Tong, Jr.· per SEC Form D · $25.1M raise · filed Apr 2024

BiotechFremont, US

Feng Wang-Johanning(Executive Officer, Director)Gary Johanning(Executive Officer)

BoardPeter Colabuono(Director)in

Board seatXiangmin Cui· per SEC Form D · $6M raise · filed Jan 2023

Co-investorsLAVLilly Asia Ventures

AI & Machine LearningBiotechDigital HealthHealthtech

Co-investorsSamsara BioCapitalvenBio Partners

Company that went public on NASDAQ in 2019 (ADPT)

Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.

BiotechDigital HealthHealthtechFoster City, US

Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)

Co-investorsF-Prime CapitalOrbiMedDeerfield Management CompanyMenlo Ventures

AK Medical (爱康医疗) develops orthopedic implants and technologies, including metal 3D-printed implants with trabecular bone-like structures, Supravit HA plasma vacuum spray coatings, surgical planning software and robotics, and personalized custom orthopedic solutions.

HardwareHealthtechMedical Devices

Co-investorsOrbiMed

A biopharmaceutical company (Ipsen, following its acquisition of Albireo Pharma) developing and commercializing medicines in oncology, rare diseases, and neuroscience for patients with high unmet medical needs.

BiotechHealthtech

Co-investorsHEALTHCARE ROYALTY PARTNERS

BiotechSeattle, US

Dr. Mitchell H Gold(Executive Officer, Director)Mitchell Gold(Executive Chairman and Chief Executive Officer)Michael Kornacker(Executive Officer, Director)Ryan Swanson(Executive Officer, Director)David Miller(Executive Officer, Director)James Paul Rickey(Senior Vice President and Chief Financial Officer)

Co-investorsFrazier Life SciencesBiotechnology Value Fund

Biopharma, acquired by Nuvation Bio (葆元医药)

Co-investorsCenova CapitalVertex Ventures China

Antengene is a biopharmaceutical company that develops therapies for cancer, with a pipeline focused on hematologic malignancies and solid tumors including Claudin 18.2, CD73, PD-L1/4-1BB bispecific, and CD24-targeting candidates.

BiotechHealthtech

Co-investorsQiming Venture PartnersBoyu Capital

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVCSofinnova Ventures+2 more

Ark Biosciences (爱科百发) is a biopharmaceutical company developing innovative drugs for respiratory diseases and pediatric conditions, with a pipeline covering RSV, ADHD, idiopathic pulmonary fibrosis (IPF), and COPD.

BiotechHealthtechShanghai, CN

Co-investorsQiming Venture Partners

Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)

BiotechEnglewood, US

Jarrett T. Disbrow(Executive Officer)Joshua R. Disbrow(Executive Officer)Gregory A. Gould(Executive Officer)

BoardMichael Macaluso(Director)

BCFoods supplies dehydrated vegetables, herbs, spices, chiles, and citrus ingredients for food manufacturers and culinary professionals.

Advanced ManufacturingFoodTech

BeyondSpring is a clinical-stage pharmaceutical company developing Plinabulin, a cancer drug candidate studied for reducing chemotherapy-induced neutropenia and, in combination with radiation and PD-1/PD-L1 inhibitors, treating patients who failed prior immune checkpoint therapy.

BiotechHealthtech

Co-investorsSangel Capital

Bioheng develops allogeneic CAR-T cell therapies for cancers and autoimmune diseases, using its Imviva platform and ANSWER technology with immune-evasion science to improve cell therapy performance and persistence.

BiotechHealthtech

Co-investorsGL VenturesHillhouse CapitalShenzhen Capital Group

Company that went public on NASDAQ in 2024 (CGON)

Clint Sever(Founder)in

Co-investorsDarwin CapitalDentsu VenturesForesite CapitalPrime PartnersACME CapitalCAVU Consumer Partners+1 more

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARCH Venture PartnersAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures

EpimAb Biotherapeutics develops bispecific antibody drugs for immuno-oncology and other high-need therapeutic areas using its proprietary FIT-Ig platform, with a pipeline of clinical programs (EMB-01, EMB-06, EMB-07) and preclinical candidates.

BiotechHealthtechShanghai, CN

Co-investorsShangBay Capital LLCTCG Labs3E Bioventures CapitalSherpa Healthcare Partners

Co-investorsBioBritCota Capital

Co-investorsRA Capital

Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.

BiotechHealthtechMedical Devices

Scott Hirsch(CEO)Dan Kaplan(CSO)

Co-investorsMPM BioImpact

GRIT Bio (沙砾生物) develops and commercializes next-generation T-cell therapies for oncology and autoimmune disease, including tumor-infiltrating lymphocyte (TIL) therapy, universal allogeneic cell therapy, in vivo CAR-T, and tumor neoantigen vaccines.

AI & Machine LearningBiotechHealthtech

Co-investorsB Capital GroupB4 Capital

Harton Therapeutics offers a GMP-ready platform for advanced 3D cell manufacturing, using a perfusion-based single-use cartridge system with automated process control to produce human cells at scale.

Advanced ManufacturingBiotechMedical Devices

Humi was a Canadian HR, payroll, and benefits software platform designed for small and medium-sized businesses in Canada.

AI & Machine LearningEnterprise SoftwareFintechHR TechSaaSToronto, CA

Kevin Kliman(Founder/CEO)inMatt Loszak(Founder/CTO)inDrew MillingtonSimon Bourgeois

Co-investors500 Global7BC Venture CapitalChartline Capital PartnersFundersClubGarage CapitalStruck Capital+2 more

Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.

AI & Machine LearningBiotechDeep TechHealthtech

Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Konrad Paszkiewicz(Chief Technology Officer)Kwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)

Co-investorsAltium CapitalClavystBioDroia VenturesFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+2 more

Co-investorsLAVLilly Asia Ventures

Incyte is a global biopharmaceutical company that develops medicines across hematology, oncology, and inflammation and autoimmunity, with clinical programs spanning areas such as dermatology.

Biotech

Insight-Med is a medtech company developing interventional cardiovascular devices, including a domestic fractional flow reserve (FFR) system approved by China's NMPA and an intravascular ultrasound (IVUS) system for precision diagnosis and treatment of cardiovascular diseases.

HealthtechMedical DevicesShenzhen, CN

Co-investorsHongShan Capital GroupQiming Venture Partners

Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.

BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US

Sean George(Executive Officer, Director)Randal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)Lee Bendekgey(Executive Officer)Geoffrey Crouse(Director)

BoardEric Aguiar(Director)in

Co-investorsCivilization Ventures Management, LlcFifty YearsManta Ray VenturesOberland CapitalPrefix CapitalTech Wildcatters+1 more

Kechow Pharma is a clinical-stage drug discovery company developing original novel small-molecule therapies for oncology and free-radical-related diseases.

BiotechHealthtech

Co-investorsQiming Venture PartnersLilly Asia Ventures